Lexeo Therapeutics, Inc. Common Stock earnings per share and revenue
On Nov 05, 2025, LXEO reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.53 USD, resulting in a 37.78% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.80% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of -0.32 USD, with revenue projected to reach -- USD, implying an decrease of -3.03% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
What were Lexeo Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Lexeo Therapeutics, Inc. Common Stock reported EPS of -$0.33, beating estimates by 37.78%, and revenue of $0.00, 0% as expectations.
How did the market react to Lexeo Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -1.8%, changed from $8.35 before the earnings release to $8.20 the day after.
When is Lexeo Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 24, 2026.
What are the forecasts for Lexeo Therapeutics, Inc. Common Stock's next earnings report?
Based on 13
analysts, Lexeo Therapeutics, Inc. Common Stock is expected to report EPS of -$0.32 and revenue of -- for Q4 2025.